ALPS Advisors’s PhaseBio Pharmaceuticals, Inc. Common Stock PHAS Stock Holding History

ALPS Advisors’s Portfolio PHAS Stock Details PHAS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-55,856	Closed	-$233K	–	869
2019 Q3	$233K	Sell	55,856 -2,919	-5%	-$23.3K	﹤0.01%	819
2019 Q2	$771K	Buy	+58,775	New	+$720K	0.01%	393

Other funds holding PHAS

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

JJIJ

Johnson & Johnson Innovation - JJDC New Brunswick, New Jersey $978M AUM 102.17% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

GTC

Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return

DCM

DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

ALPS Advisors's PHAS Position: Q4 2019 in Review

ALPS Advisors sold out of PhaseBio Pharmaceuticals, Inc. Common Stock (PHAS) in Q4 2019, closing a stake of 55,856 shares — an estimated $233K sold.

ALPS Advisors first reported a position in PHAS in Q2 2019 and held it in 2 quarters. The position peaked at $771K in Q2 2019. 51 funds tracked by Wall St. Rank hold PHAS as of Q4 2019.

ALPS Advisors reported no remaining PhaseBio Pharmaceuticals, Inc. Common Stock position as of Q4 2019 after selling out during the quarter.
ALPS Advisors sold 55,856 PhaseBio Pharmaceuticals, Inc. Common Stock shares in Q4 2019, an estimated $233K.
ALPS Advisors first reported a position in PhaseBio Pharmaceuticals, Inc. Common Stock in Q2 2019 and held it in 2 quarters.
ALPS Advisors's PhaseBio Pharmaceuticals, Inc. Common Stock position peaked at $771K in Q2 2019.
51 funds tracked by Wall St. Rank held PhaseBio Pharmaceuticals, Inc. Common Stock as of Q4 2019.

Based on ALPS Advisors's 13F filing for Q4 2019, filed 7 Feb 2020.